New Logo.png
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
07 mars 2024 08h00 HE | Provectus Biopharmaceuticals Inc.
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in vivo KNOXVILLE, TN, March 07,...
AKOYA Bio - Logo - Standard Centered.png
Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
17 oct. 2023 10h22 HE | Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that researchers from Akoya Biosciences and The...
Vaccinex logo
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis
09 mars 2023 08h00 HE | Vaccinex, Inc.
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study...
Vaccinex logo
Vaccinex Announces $6.6 Million Private Placement
27 janv. 2022 16h15 HE | Vaccinex, Inc.
Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) --...
Vaccinex logo
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer
26 janv. 2022 08h00 HE | Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
Hookipa Pharma Logo Square.png
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
18 janv. 2022 07h00 HE | HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
Vaccinex logo
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
10 nov. 2021 08h00 HE | Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Kura Oncology Logo
Kura Oncology Reports First Quarter 2021 Financial Results
06 mai 2021 16h04 HE | Kura Oncology, Inc.
– Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window – – KOMET-001 trial amended to include Phase 1b expansion...
Vaccinex logo
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
21 avr. 2021 08h00 HE | Vaccinex, Inc.
ROCHESTER, N.Y., April 21, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
FStar.jpg
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
19 avr. 2021 09h27 HE | F-star Therapeutics, Inc.
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United...